Podcasts about infectious diseases

We kicked off the program with four news stories and different guests on the stories we think you need to know about! Proposed bill which would allow law enforcement to seize vehicles involved in illegal street takeovers and car meetups.Guest: Rep. Christopher Markey – proposed the MA bill New Flu Mutation and What It Could Mean for the U.S. – some predictions saying it could be the worst season in a decade.Guest: Dr. Daniel Kuritzkes - Chief of Infectious Diseases at Brigham and Women’s Hospital Why you should embrace new technology as you age.Guest: Richard Sima – neuroscientist & Brain Matters Columnist for WaPO Thanksgiving food that could harm pets. What you need to know…Guest: Dr. Gary Richter - veterinarian and pet wellness expert – created the dog food brand: Ultimate Pet NutritionSee omnystudio.com/listener for privacy information.

It's World AMR Awareness Week (WAAW) and we have prepared a special episode in light of that. In this week's Communicable, Navaneeth Narayanan and Thomas Tängdén host Aula Abbara (London, UK), Guido Granata (Rome, Italy) and Tuomas Aro (Helsinki, Finland) to discuss the phenomenon of AMR in conflict and crisis zones. They elaborate on how difficult conditions and austere environments amplify the spread of AMR, drawing on findings from the ongoing conflicts in Ukraine, Gaza, Syria and other regions. Other topics covered include adapting antimicrobial stewardship and infection prevention and control (IPC) practices as well as the need for genuine political will and international collaboration to end conflicts and their exacerbation on AMR.This episode follows the webinar “Beyond the frontlines” organised by ESCMID's AMR Action Subcommittee for WAAW 2025, featuring the same guests, and is available on ESCMID Media. This Communicable episode was peer reviewed by Arjana Zerja of Mother Theresa University Hospital Centre, Tirana, Albania.  Related ESCMID and Communicable mediaESCMID Media, Part 1: Beyond the frontlines - tackling AMR in conflict and crisis zones, webinar Communicable episode 11: Nightmare series, part 2 – how to deal with carbapenemase producers Communicable episode 16: Climate change and infections – effects on clinical practice & sustainabilityResourcesTrainee Association of ESCIMD (TAE) Doctors without Borders (Médecins sans Frontières), Antibiogo, https://www.antibiogo.org/Doctors without Borders (Médecins sans Frontières), Mini-lab, https://fondation.msf.fr/en/projects/mini-lab Further ReadingAbbara A, et al. Unravelling the linkages between conflict and antimicrobial resistance. NPJ Antimicrob Resist. 2025. DOI: 10.1038/s44259-025-00099-yAbbara A, et al. A summary and appraisal of existing evidence of antimicrobial resistance in the Syrian conflict. Int J Infect Dis. 2018. DOI: 10.1016/j.ijid.2018.06.010Abu-Shomar R, et al. Multidrug-resistant Pseudomonas isolated from water at primary health care centers in Gaza, Palestine: a cross-sectional study. IJID Reg. 2025. DOI: 10.1016/j.ijregi.2025.100671Aldbis A, et al. The lived experience of patients with conflict associated injuries whose wounds are affected by antimicrobial resistant organisms: a qualitative study from northwest Syria. Confl Health. 2023. DOI: 10.1186/s13031-023-00501-4Aro T, et al. War on antimicrobial resistance: high carriage rates of multidrug-resistant bacteria among war-injured Ukrainian refugees. Clin Microbiol Infect. 2025. DOI: 10.1016/j.cmi.2025.07.010  Bazzi W, et al. Heavy Metal Toxicity in Armed Conflicts Potentiates AMR in A. baumannii by Selecting for Antibiotic and Heavy Metal Co-resistance Mechanisms. Front Microbiol. 2020. DOI: 10.3389/fmicb.2020.00068 Dewachi O. War Biology and Antimicrobial Resistance: The Case of Gaza, AMR Insights, 2024.Granata G, et al. The impact of armed conflict on the development and global spread of antibiotic resistance: a systematic review. Clin Microbiol Infect. 2024. DOI: 10.1016/j.cmi.2024.03.029 Huang XZ, et al. Molecular analysis of imipenem-resistant Acinetobacter baumannii isolated from US service members wounded in Iraq, 2003-2008. Epidemiol Infect. 2012. DOI: 10.1017/S0950268811002871Hujer KM, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother. 2006. DOI: 10.1128/AAC.00778-06Karah N, et al. Teleclinical Microbiology: An Innovative Approach to Providing Web-Enabled Diagnostic Laboratory Services in Syria. Am J Clin Pathol. 2022. DOI: 10.1093/ajcp/aqab160Keen EF 3rd, et al. Evaluation of potential environmental contamination sources for the presence of multidrug-resistant bacteria linked to wound infections in combat casualties. Infect Control Hosp Epidemiol. 2012. DOI: 10.1086/667382Murray CK, et al. Recovery of multidrug-resistant bacteria from combat personnel evacuated from Iraq and Afghanistan at a single military treatment facility. Mil Med. 2009. DOI: 10.7205/milmed-d-03-8008Petersen K, et al. Diversity and clinical impact of Acinetobacter baumannii colonization and infection at a military medical center. J Clin Microbiol. 2011. DOI: 10.1128/JCM.00766-10Scott P, et al. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis. 2007. DOI: 10.1086/518170Sensenig RA, et al. Longitudinal characterization of Acinetobacter baumannii-calcoaceticus complex, Klebsiella pneumoniae, and methicillin-resistant Staphylococcus aureus colonizing and infecting combat casualties. Am J Infect Control. 2012. DOI: 10.1016/j.ajic.2011.03.025World Health Organization. Fourth WHO Global Evidence Review on Health and Migration stresses that equitable access to and appropriate use of antibiotics for refugees and migrants is essential to tackling Antimicrobial Resistance, News, 2022.

Looming over the Liberals is whether Prime Minister Mark Carney's first budget will pass its final vote on Monday in the House of Commons. So far, no other political party has given a sign they will support it. Green Party Leader Elizabeth May discusses whether she'll change her mind and vote with the Liberals on the budget. Christopher Nardi of the National Post and Tonda MacCharles of the Toronto Star weigh in on where the government can get the last two votes it needs or if we're heading into another election this year. Mark Carney announced more major projects to spur Canada's economic growth. Rick Smith of the Canadian Climate Institute tells The House how Canada's push to expand mining and energy projects is going down at the United Nations climate change conference in Brazil. Plus, as Canada loses its measles elimination status Dr. Natasha Crowcroft, Vice President of the Infectious Diseases and Vaccination Programs Branch at the Public Health Agency of Canada explains what needs to be done to win it back. And: J.D.M. Stewart, author of The Prime Ministers: Canada's Leaders and the Nation they Shaped, takes Catherine Cullen on a tour of the monuments erected on Parliament Hill to commemorate Canada's leaders. Who were they, what were their funny foibles, and will Canada ever see a statue of Stephen Harper or Justin Trudeau? This episode features the voices of: Elizabeth May, Green Party LeaderChristopher Nardi, National Post parliamentary reporterTonda MacCharles, Toronto Star Ottawa bureau chief Rick Smith, President of the Canadian Climate InstituteDr. Natasha Crowcroft, Vice President of the Infectious Diseases and Vaccination Programs Branch at the Public Health Agency of Canada J.D.M. Stewart, author of The Prime Ministers: Canada's Leaders and the Nation they Shaped

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members.AzAAP would like to acknowledge the generous support of the podcast by the Arizona Department of Health Services through the Title V Maternal and Child Health Services Block Grant funding. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

In this episode of the RCP Medicine Podcast, Dr Lisa Hamza, HIV and Sexual Health Consultant at St George's Hospital, London, joins Dr Rohan Mehra, Infectious Diseases and Microbiology Registrar, to explore the evolving landscape of HIV care. Together, they delve into the virology, history, and treatment of HIV, highlighting the remarkable progress made over the past four decades - from the early days of the epidemic to today's cutting-edge therapies and prevention strategies.Dr Hamza shares insights from her work as HIV Network Lead in South West London and co-chair of the HIV London Forum, discussing the challenges of stigma, late diagnosis, and health inequalities. The conversation also covers the UK's HIV Action Plan, the impact of opt-out testing, and the promise of long-acting treatments and pre-exposure prophylaxis (PrEP). This episode is a powerful reminder of how far we've come and how much further we must go to reach zero transmissions, zero deaths, and zero stigma.RCP Links Education Events Membership Improving care Policy and campaigns RCP Social Media Instagram LinkedIn Facebook X Bluesky Music: Episode 50 onward - Bensound.com Episodes 1 - 49 'Impressive Deals' - Nicolai Heidlas

The post 144 GU Infectious disease and getting more questions right appeared first on Physician Assistant Exam Review.

On episode #93 of the Infectious Disease Puscast, Daniel and Sara review the infectious disease literature for the weeks of 10/23/25 – 11/10/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral High Prevalence of Varicella Zoster Virus Infection among Persons with Suspect Mpox Cases during an Mpox Outbreak in Kenya, 2024 (ASTMH: AJTMH) Earlier initiation of treatment following HIV acquisition reduces non-AIDS-defining malignancy risk (CID) TWiV 1267: A cancer vaccine and an mpox treatment (MicrobeTV) Cancers Caused by HPV (CDC: Human Papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of the National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine—A Systematic Review (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendations (CDC: Vaccines & Immunizations) Bacterial Consequences of Delaying Surgical Intervention in Patients with Native Joint Septic Arthritis (OFID) Fungal The Last of US Season 2 (YouTube) Adjunctive corticosteroids in non-AIDS patients with severe Pneumocystis jirovecii pneumonia (PIC): a multicentre, double-blind, randomised controlled trial (LANCET: Respiratory Medicine) Nasal Iodophor to Reduce Candidozyma auris Nasal Carriage in Nursing Home Residents (OFID) Epidemiology of Invasive Fungal Disease in Pediatric Heart Transplant Recipients (Journal of Pediatric Infectious Diseases Society) Mapping the Geographic Distribution of Dimorphic Mycoses Using a US Commercial Insurance Database (OFID) Genomic Dynamics of the Emergent Candida auris: Exploring Climate-dependentTrends (OFID) Parasitic Evaluation of a One Health public health program based on minimum inputs to control Taenia solium in Madagascar (PLoS Neglected Tropical Diseases) Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood (CID) Miscellaneous Amplifying Our Voices: Fostering Advocacy in Infectious Diseases Fellowship(OFID) Plant-Based Diets and Climate Change, A Perspective for Infectious Disease Provider (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Joshua Barocas is an associate professor of medicine at the University of Colorado Anschutz Medical Campus. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal. J.A. Barocas. The Erosion of Harm Reduction. N Engl J Med 2025;393:1865-1867. B.A. Barsky, A. Caplan-Bricker, and C. Robertson. Religious Liberty as a Shield for Public Health — The Case of Overdose-Prevention Centers. N Engl J Med 2025;393:1867-1869.

In this episode, Katlyn Moss talks to Shannon Dowler, a Family Medicine physician about the recent increase in syphilis cases and what can be done to treat and prevent it.  They will discuss why syphilis often goes undiagnosed and untreated, along with the barriers that health systems, clinicians, and public health professionals are currently facing in their work to control syphilis and other infectious diseases. They also talk about the special implications for pregnant patients and their babies.  Dr. Dowler provides plenty of information and action items on treating syphilis as well as how it can be prevented.  Resources Dr. Shannon Dowler, MDDr. Dowler's You Tube Channel- Health Education RapsCDC STI Treatment Guidelines -including downloadable appNC DHHS Syphilis Resources for ProvidersWe would love your feedback on our podcast!  Please take our listener survey to provide your comments.Follow us on FacebookFollow us on InstagramMusic credit: "Carefree" Kevin MacLeod (incompetech.com) Licensed under Creative Commons: By Attribution 4.0 Licensehttp://creativecommons.org/licenses/by/4.0/Please provide feedback here:https://redcap.mahec.net/redcap/surveys/?s=XTM8T3RPNK

Overview: In this episode, Dr Joel Gallant gives a history of antiretroviral therapy and HIV drug resistance, drawing on his personal and professional experience beginning in the early 1980s. The views expressed are those of the panelist and not necessarily Gilead Sciences, Inc. The information provided in this podcast is not intended to be and should not be understood to provide medical advice. Listeners should note that our discussions in this episode are relevant to the USA only and may not be appropriate for other regions. This episode was recorded in August 2023 and the content reflects the information available at that time. Guest: Joel Gallant, MD, MPH    For more information, please visit: https://www.pri-med.com/clinical-resources/curriculum/hiv-in-focus    References AIDSVu.org. New HIV diagnoses. 2023. Available from: https://aidsvu.org/local-data/united-states/south/ (Accessed May 19, 2025) AIDSVu.org was developed by the Rollins School of Public Health at Emory University in partnership with Gilead Sciences, Inc. Alonso A, de Irala J. Strategies in HIV prevention: the A-B-C approach. Lancet 2004;364:1033. Available from: https://doi.org/10.1016/s0140-6736(04)17050-5 Bacheler L, Jeffrey S, Hanna G et al. Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. J Virol 2001;75:4999–5008. Available from: https://doi.org/10.1128/jvi.75.11.4999-5008.2001 Barré-Sinoussi F, Chermann JC, Rey F et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983;220:868–71. Available from: https://doi.org/10.1126/science.6189183 Bayer R, Edington C. HIV testing, human rights, and global AIDS policy: exceptionalism and its discontents. J Health Polit Policy Law 2009;34:301–23. Available from: https://doi.org/10.1215/03616878-2009-002 Centers for Disease Control and Prevention. Pneumocystis pneumonia – Los Angeles. MMWR Morb Mortal Wkly Rep 1981;30:250-2. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/june_5.htm Centers for Disease Control and Prevention. Preventing HIV. 2024. Available from: https://www.cdc.gov/hiv/prevention/index.html (Accessed May 22, 2025) Cohen MS, Chen YQ, McCauley M et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493–505. Available from: https://doi.org/10.1056/NEJMoa1105243 Cuevas JM, Geller R, Garijo R et al. Extremely high mutation rate of HIV-1 in vivo. PLoS Biol 2015;13:e1002251. Available from: https://doi.org/10.1371/journal.pbio.1002251 Department of Health and Human Services. Guidelines for the use of antiretroviral agents in adults and adolescents with HIV. 2024. Available from: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/optimizing-antiretroviral-therapy (Accessed May 19, 2025) Dragovic G. Acute pancreatitis in HIV/AIDS patients: an issue of concern. Asian Pac J Trop Biomed 2013;3:422–425. Available from: https://doi.org/10.1016%2FS2221-1691(13)60091-X Eron JJ, Benoit SL, Jemsek J et al. Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party. N Engl J Med 1995;333:1662–9. Available from: https://doi.org/10.1056/nejm199512213332502 Gandhi RT, Tashima KT, Smeaton LM et al. Long-term outcomes in a large randomized trial of HIV-1 salvage therapy: 96-week results of AIDS clinical trials group A5241 (OPTIONS). J Infect Dis 2020;221:1407–15. Available from: https://doi.org/10.1093/infdis/jiz281 Getting to Zero San Francisco. HIV epidemiology annual report 2017. 2022. Available from: https://gettingtozerosf.org/getting-to-zero-resources/hiv-report-2017/ (Accessed May 22, 2025) Global Fund. About the Global Fund. 2024. Available from: https://www.theglobalfund.org/en/about-the-global-fund/ (Accessed May 19, 2025) Gulick RM, Lalezari J, Goodrich J et al. Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 2008;359:1429–41. Available from: https://doi.org/10.1056/NEJMoa0803152 Gulick RM, Mellors JW, Havlir D et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med 1997;337:734–9. Available from: https://doi.org/10.1056/nejm199709113371102 Haubrich R, Berger D, Chiliade P et al. Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients. AIDS 2007;21:F11–8. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b47 HIV Prevention Trials Network. HPTN 052. 2023. Available from: https://www.hptn.org/research/studies/hptn052 (Accessed May 19, 2025) HIV.gov. HIV and AIDS timeline. 2024. Available from: https://www.hiv.gov/hiv-basics/overview/history/hiv-and-aids-timeline/ (Accessed May 19, 2025) HIVinfo.NIH.gov. FDA approval of HIV medicines. 2024. Available from: https://hivinfo.nih.gov/understanding-hiv/infographics/fda-approval-hiv-medicines (Accessed May 19, 2025) i-base. Cross-resistance by drug class. 2025. Available from: https://i-base.info/guides/changing/cross-resistance (Accessed May 19, 2025) Iyidogan P, Anderson KS. Current perspectives on HIV-1 antiretroviral drug resistance. Viruses 2014;6:4095–139. Available from: https://doi.org/10.3390/v6104095 Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med 2003;348:2175–85. Available from: https://doi.org/10.1056/NEJMoa035026 Landovitz RJ, Donnell D, Clement ME et al. Cabotegravir for HIV prevention in cisgender men and transgender women. N Engl J Med 2021;385:595–608. Available from: https://doi.org/10.1056/NEJMoa2101016 Larder BA, Darby G, Richman DD. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science 1989;243:1731–4. Available from: https://doi.org/10.1126/science.2467383 Lau B, Gange SJ, Moore RD. Risk of non-AIDS-related mortality may exceed risk of AIDS-related mortality among individuals enrolling into care with CD4+ counts greater than 200 cells/mm3. J Acquir Immune Defic Syndr 2007;44:179–87. Available from: https://doi.org/10.1097/01.qai.0000247229.68246.c5 Lucas C. The San Francisco model and the nurses of Ward 5B. Lancet HIV 2019;6:E819. Available from: https://doi.org/10.1016/S2352-3018(19)30267-X Madruga JV, Cahn P, Grinsztejn B et al. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29–38. Available from: https://doi.org/10.1016/s0140-6736(07)61047-2 Marcelin AG. Resistance to nucleoside reverse transcriptase inhibitors. In: Geretti AM, editor. Antiretroviral Resistance in Clinical Practice. London: Mediscript; 2006. Chapter 1. Available from: https://www.ncbi.nlm.nih.gov/books/NBK2241/ Margolis AM, Heverling H, Pham PA et al. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26–39. Available from: https://doi.org/10.1007/s13181-013-0325-8 Moore RD, Creagh-Kirk T, Keruly J et al. Long-term safety and efficacy of zidovudine in patients with advanced human immunodeficiency virus disease. Zidovudine Epidemiology Study Group. Arch Intern Med 1991;151:981–6. Available from: https://doi.org/10.1001/archinte.1991.00400050123023 National Institute of Allergy and Infectious Diseases. HIV Undetectable = Untransmittable (U = U), or treatment as prevention. 2019. Available from: https://www.niaid.nih.gov/diseases-conditions/treatment-prevention (Accessed May 19, 2025) Nelson MR, Katlama C, Montaner JS et al. The safety of […] for the treatment of HIV infection in adults: the first 4 years. AIDS 2007;21:1273–81. Available from: https://doi.org/10.1097/QAD.0b013e3280b07b33 New York State Department of Health. Pre-exposure prophylaxis (PrEP) to prevent HIV infection: question and answers. 2012. Available from: https://www.health.ny.gov/publications/0265/ (Accessed May 22, 2025) Overton ET, Richmond G, Rizzardini G et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with human immunodeficiency virus 1 type 1 infection: 152-week results from ATLAS-2M, a randomized, open-label, phase 3b, noninferiority study. Clin Infect Dis 2023;76:1646–54. Available from: https://doi.org/10.1093/cid/ciad020 Pollak EB, Parmar M. Indinavir. In: StatPearls. Treasure Island (FL): StatPearls Publishing, 2023. Available from: https://www.ncbi.nlm.nih.gov/books/NBK554396/ (Accessed May 19, 2025) Richman DD, Fischl MA, Grieco MH et al. The toxicity of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med 1987;317:192–7. Available from: https://doi.org/10.1056/nejm198707233170402 Schmit JC, Ruiz L, Clotet B et al. Resistance-related mutations in the HIV-1 protease gene of patients treated for 1 year with the protease inhibitor ritonavir (ABT-538). AIDS 1996;10:995–9. Available from: https://doi.org/10.1097/00002030-199610090-00010 Siliciano JD, Kajdas J, Finzi D et al. Long-term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9:727–8. Available from: https://doi.org/10.1038/nm880 Steigbigel RT, Cooper DA, Kumar PN et al. Raltegravir with optimized background therapy for resistant HIV-1 infection. N Engl J Med 2008;359:339–54. Available from: https://doi.org/10.1056/NEJMoa0708975 TIME. Man of the year. 1996. Available from: https://time.com/vault/issue/1996-12-30/page/1/ (Accessed May 19, 2025) U.S. President's Emergency Plan for AIDS Relief (PEPFAR). About us. 2025. Available from: https://www.state.gov/about-us-pepfar/ (Accessed May 19, 2025)

Sinn Fein's Pádraig Mac Lochlainn raised the issue of long Covid and renewed calls for the State to recognise long Covid as an occupational illness in line with other EU member states.It was found that the Department of Social Protection reviewed the EU recommendation and determined that Covid does not meet the criteria required for recognition in respect of the Social Welfare Acts.But, what is life like for those who still suffer from long Covid?Joining Ciara Doherty to discuss is Jennifer, who has been dealing with long Covid since her first infection in 2020 and Professor Jack Lambert, Consultant in Infectious Diseases, with a special interest in long Covid.

Former CDC Director Dr. Robert Redfield, who once stood beside Dr. Fauci leading America's COVID response, now says Washington got it wrong – and warns the next deadly pandemic may already be here. In “Redfield's Warning” he blasts the lockdowns, mandates, and censorship that defined the pandemic era. Now a MAHA advocate, he argues the government ignored evidence, failed to protect high-risk groups, and insists gain-of-function research and poor biosecurity are still the greatest dangers to humanity. Dr. Robert Redfield is a virologist, infectious disease expert, and former Director of the CDC. He served on the White House Coronavirus Task Force and Operation Warp Speed board. He co-founded the University of Maryland's Institute of Human Virology and was Chief of Infectious Diseases at UMD School of Medicine. A Georgetown Medical graduate, he advised President Bush on HIV/AIDS and Governor Hogan on public health. He currently practices at GBMC Health Partners. Learn more at https://gbmc.org⠀John Solomon is an award-winning investigative journalist and the founder of Just the News. He previously worked for the Associated Press, The Washington Post, The Washington Times, and The Hill. Follow at https://x.com/jsolomonReports⠀Paul Mauro is a Fox News contributor and attorney at DeMarco Law. He previously served as Commanding Officer of the NYPD Legal Bureau and Executive Officer of the Intelligence Operations and Analysis Bureau. He holds an MPA from Harvard and a JD from Fordham Law. Follow at https://x.com/PaulDMauro 「 SUPPORT OUR SPONSORS 」 Find out more about the brands that make this show possible and get special discounts on Dr. Drew's favorite products at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/sponsors⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠  ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠• FATTY15 – The future of essential fatty acids is here! Strengthen your cells against age-related breakdown with Fatty15. Get 15% off a 90-day Starter Kit Subscription at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/fatty15⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • PALEOVALLEY - "Paleovalley has a wide variety of extraordinary products that are both healthful and delicious,” says Dr. Drew. "I am a huge fan of this brand and know you'll love it too!” Get 15% off your first order at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://drdrew.com/paleovalley⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ • VSHREDMD – Formulated by Dr. Drew: The Science of Cellular Health + World-Class Training Programs, Premium Content, and 1-1 Training with Certified V Shred Coaches! More at https://drdrew.com/vshredmd • THE WELLNESS COMPANY - Counteract harmful spike proteins with TWC's Signature Series Spike Support Formula containing nattokinase and selenium. Learn more about TWC's supplements at ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twc.health/drew⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ 「 MEDICAL NOTE 」 Portions of this program may examine countervailing views on important medical issues. Always consult your physician before making any decisions about your health. 「 ABOUT THE SHOW 」 Ask Dr. Drew is produced by Kaleb Nation (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://kalebnation.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠) and Susan Pinsky (⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://twitter.com/firstladyoflov⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠e⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠). This show is for entertainment and/or informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment. Executive Producers • Kaleb Nation - ⁠⁠⁠https://kalebnation.com⁠⁠⁠ • Susan Pinsky - ⁠⁠⁠https://x.com/firstladyoflove⁠⁠⁠ Content Producer & Booking • Emily Barsh - ⁠⁠⁠https://x.com/emilytvproducer⁠⁠⁠ Hosted By • Dr. Drew Pinsky - ⁠⁠⁠https://x.com/drdrew⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

In his weekly clinical update, Dr. Griffin with Vincent Racaniello discusses the link between in utero SARS-CoV-2 infection and poor neurodevelopment outcomes, the use of an mRNA vaccine as an anti-cancer therapy, why one should receive the HPV vaccine, asymptomatic H5N1 isolations in humans, and H5N1 on turkey farms, before Dr. Griffin deep dives into recent statistics on the measles epidemic, RSV, influenza and SARS-CoV-2 infections, the Wasterwater Scan dashboard, Johns Hopkins measles tracker, how two vaccinated physicians became infected with measles, effective of COVID-19 vaccine for children, where to find PEMGARDA, how to access and pay for Paxlovid, can you be retreated with Paxlovid, long COVID treatment center, where to go for answers to your long COVID questions, how a specific antibody type may associate with recovery from long COVID, if use of a probiotic is helpful to treat mild COVID-19, if vaccination helps prevent long in adolescents and contacting your federal government representative to stop the assault on science and biomedical research. Subscribe (free): Apple Podcasts, RSS, email Become a patron of TWiV! Links for this episode Neurodevelopmental Outcomes of 3-Year-Old Children Exposed to Maternal Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection in Utero (Obstetrics & Gynecology) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1267: A cancer vaccine and an mpox treatment (microbeTV: TWiV1267) Cancers Caused by HPV (CDC: Human papillomavirus (HPV)) Circulating tumor human papillomavirus DNA whole genome sequencing enables human papillomavirus-associated oropharynx cancer early detection (Journal of National Cancer Institute) Impact of Vaccinating Adult Women Who Are HPV-Positive or with Confirmed Cervical SIL with the 9-Valent Vaccine (Viruses) ACIP Shared Clinical Decision-Making Recommendations (CDC: Advisory Committee on Immunization Practices (ACIP)) HPV Vaccination Recommendation (CDC: Vaccines & Immunizations) Asymptomatic Human Infections With Avian Influenza A(H5N1) Virus Confirmed by Molecular and Serologic Testing (JAMA: OPEN Network) Review: Human H5N1 avian flu cases can be asymptomatic, and the virus likely spreads among people (CIDRAP) Avian flu strikes turkey farms in Dakotas, large egg facility in California (CIDRAP) Another Doctor at Ichilov Contracts Measles After Treating Unvaccinated Child (gov.il) Wastewater for measles (WasterWater Scan) Measles cases and outbreaks (CDC Rubeola) Tracking Measles Cases in the U.S. (Johns Hopkins) Measles vaccine recommendations from NYP (jpg) Weekly measles and rubella monitoring (Government of Canada) Measles (WHO) Get the FACTS about measles (NY State Department of Health) Measles (CDC Measles (Rubeola)) Measles vaccine (CDC Measles (Rubeola)) Presumptive evidence of measles immunity (CDC) Contraindications and precautions to measles vaccination (CDC) Measles (CDC Measles (Rubeola)) Adverse events associated with childhood vaccines: evidence bearing on causality (NLM) Measles Vaccination: Know the Facts (ISDA: Infectious Diseases Society of America) Deaths following vaccination: what does the evidence show (Vaccine) Influenza: Waste water scan for 11 pathogens (WastewaterSCan) US respiratory virus activity (CDC Respiratory Illnesses) Respiratory virus activity levels (CDC Respiratory Illnesses) Weekly surveillance report: clift notes (CDC FluView) ACIP Recommendations Summary (CDC: Influenza) Influenza Vaccine Composition for the 2025-2026 U.S. Influenza Season (FDA) RSV: Waste water scan for 11 pathogens (WastewaterSCan) Respiratory Diseases (Yale School of Public Health) US respiratory virus activity (CDC Respiratory Illnesses) RSV-Network (CDC Respiratory Syncytial virus Infection) Vaccines for Adults (CDC: Respiratory Syncytial Virus Infection (RSV)) Economic Analysis of Protein Subunit and mRNA RSV Vaccination in Adults aged 50-59 Years (CDC: ACIP) Waste water scan for 11 pathogens (WastewaterSCan) COVID-19 deaths (CDC) Respiratory Illnesses Data Channel (CDC: Respiratory Illnesses) COVID-19 national and regional trends (CDC) COVID-19 variant tracker (CDC) SARS-CoV-2 genomes galore (Nextstrain) Antigenic and Virological Characteristics of SARS-CoV-2 Variant BA.3.2, XFG, and NB.1.8.1 (bioRxiV) Vascular and inflammatory diseases after COVID-19 infection and vaccination in children and young people in England (LANCET: Child & Adolescent Health) Where to get pemgarda (Pemgarda) EUA for the pre-exposure prophylaxis of COVID-19 (INVIYD) Infusion center (Prime Fusions) CDC Quarantine guidelines (CDC) NIH COVID-19 treatment guidelines (NIH) Drug interaction checker (University of Liverpool) Help your eligible patients access PAXLOVID with the PAXCESS Patient Support Program (Pfizer Pro) Understanding Coverage Options (PAXCESS) Real-World Effectiveness of Nirmatrelvir-Ritonavir in Preventing Coronavirus Disease 2019–Associated Hospitalization (CID) Infectious Disease Society guidelines for treatment and management (ID Society) Molnupiravir safety and efficacy (JMV) Convalescent plasma recommendation for immunocompromised (ID Society) What to do when sick with a respiratory virus (CDC) Managing healthcare staffing shortages (CDC) Anticoagulation guidelines (hematology.org) Daniel Griffin's evidence based medical practices for long COVID (OFID) Long COVID hotline (Columbia : Columbia University Irving Medical Center) The answers: Long COVID SARS-CoV-2 spike-specific IgG4 class switching associates with clinical recovery in Long COVID (Journal of Infection) Efficacy of Lactococcus lactis Strain Plasma in Patients with Mild COVID-19 (Infectious Diseases and Therapy) Preventive effect of vaccination on long COVID in adolescents with SARS-CoV-2 infection (Vaccine) Reaching out to US house representative Letters read on TWiV 1268 Dr. Griffin's COVID treatment summary (pdf) Timestamps by Jolene Ramsey. Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to daniel@microbe.tv Content in this podcast should not be construed as medical advice.

Let's Talk ID hosts, Buddy Creech, MD, MPH, FPIDS, Mati Hlatshwayo Davis, MD, MPH, FIDSA and Paul Sax, MD, FIDSA reunite live at IDWeek 2025 to share their hottest takes on infectious diseases and public health. They discuss the controversial dismantling of CDC, exciting breakthroughs in treating staph aureus bacteremia, and shifts that could shape the future of the field.

Dr. Jose Montero, Professor of Medicine at the University of South Florida Morsani College of Medicine, presents an overview of the management of Surgical Site Infections (SSIs) for an Infectious Diseases specialist. The lecture opens with a discussion of the history of SSI management, reviewing milestones in the prevention of these infections and their discoverers, from Semmelweis, to Lister, to Koch. Next, the sources of SSIs are differentiated. Dr. Montero then reviews risk factors for SSIs, and then covers prevention strategies. A major strategy for infection prevention during surgery is antimicrobial prophylaxis, and Dr. Montero highlights systemic and topical antimicrobials useful for this purpose, including timing of administration and duration. Lastly, the speaker focuses on MRSA as an SSI pathogen and offers special considerations for this organism.

Our inaugural episode of Season 2 of The Contagion Podcast opens as show producer Dr. Richard Oehler and show co-host Dr. Vivian Vega reflect on how much has changed in the fields of infectious diseases and public health since our Season 1 finale was posted in June. Drs. Oehler and Vega share some very timely updates in their ID news segment--recounting changes at the CDC as well as several important epidemiological and research developments.  Next, Dr. Vega and our special guest, Infectious Diseases specialist and former military physician Dr. Patrick Danaher transition to a chilling yet timely exploration of bioterrorism and biological warfare, threats that no longer garner the attention they once did a couple of decades ago. The two recount bizarre early attempts — like firing rabid dog saliva or trading leprosy-tainted wine — that reveal how little was once understood about contagion. But the tone shifts as the conversation moves on to the 1984 Salmonella attack in The Dalles, Oregon, America's first large-scale bioterrorism event. A cult known as the Rajneeshees deliberately contaminated restaurant salad bars to sway a local election, sickening more than 750 people. Through detailed epidemiologic analysis, the hosts explain how investigators connected the outbreak to the commune and why this case remains a critical public-health lesson in surveillance and preparedness. From there, the discussion expands to bioweapons — cheap, concealable, and capable of mass panic. The doctors compare the costs of biological, chemical, and nuclear weapons, underscoring why pathogens are often called “the poor man's nuclear bomb.” They walk through the CDC's Category A threat list — including anthrax, smallpox, plague, and viral hemorrhagic fevers — and dissect what makes these microbes so devastating. Listeners are then transported to the aftermath of 9/11, when anthrax-laden letters reignited national fears of invisible enemies. The podcast reconstructs the FBI investigation, profiles scientist Bruce Ivins, and explains how this attack reshaped U.S. biodefense policy, from Project BioShield to the Strategic National Stockpile. The last segment turns to smallpox, humanity's “crown jewel” of eradication turned nightmare scenario. Through insights from Soviet defector Ken Alibek and modern concerns about synthetic biology, the episode reveals why smallpox remains one of the most feared potential bioweapons — despite being officially eradicated in 1980. Blending medical insight, historical storytelling, and wry humor, Contagion Pod's Season 2 premiere reminds us that while pandemics capture headlines, the threat of bioterrorism never truly disappears.Dr Vega would like to thank her friend Job Meiller for his musical contribution to our segment breaks. Thank you Job!Thanks also to Dr. Ana Velez, our artistic contributor, for her original painting, “Biohazard Dream,” used in our episode thumbnail.

Michael chats with Martin Price, Executive Chairman and CEO of HealthTrackRx. Together, they discuss how HealthTrackRx has transformed infectious disease testing with next-morning results, how the company has ensured its technology delivers on speed and accuracy for patients and providers, how its testing has influenced prescribing behavior and improved patient outcomes, balancing scaling operations with maintaining clinical excellence and high-quality results, fostering a culture of innovation and accountability across teams while remaining patient-focused, trends in outpatient diagnostics, and much more. To learn more about HealthTrackRx, visit www.HealthTrackRx.com.

Cold sores and herpes, shingles and chicken pox, and a range of other viral annoyances, as well as often being very painful, are all latent viruses. Waiting for your immunity to drop to strike, kicking you while you're down. 

Once confined to the tropics, dengue is spreading via its vector, the Aedes mosquito, to more temperate regions, causing increases in global morbidity, mortality and cost. In 2019, the WHO recognised dengue as one of the top ten global health threats alongside climate change and antimicrobial resistance [1]. In this episode of Communicable, Annie Joseph and Nav Narayanan welcome two dengue experts, André Siqueira of the non-profit Drugs for Neglected Diseases Initiative based in Geneva, Switzerland (Rio de Janeiro, Brazil), and Steven Lim of the Raja Permaisuri Bainun Hospital (Ipoh, Malaysia). Together, they discuss the epidemiology, clinical presentation and management of dengue including comparisons to other arboviral infections like zika and chikungunya, and the heightened risk of disease for vulnerable populations such as pregnant women and those with comorbidities. The conversation also highlights innovative vector-control strategies and candidate therapeutics currently under investigation. This episode was edited by Kathryn Hostettler and peer reviewed by Loora Grünvald of the University of Tartu, Estonia. Resources:Drug for Neglected Diseases (DNDi), https://dndi.org/ Dengue Alliance, https://dndi.org/global-networks/dengue-alliance/ Qdenga vaccine information: https://travelhealthpro.org.uk/news/763/qdenga-dengue-vaccine-guidanceDengavaxia vaccine information: https://www.cdc.gov/dengue/hcp/vaccine/index.html References: World Health Organization, Ten threats to global health in 2019.Further reading: Treating a feverish planet: The Dengue Alliance, a video

Lessons from Rwanda's Marburg Virus Outbreak and Building Resilient Systems in Global EM. Hosts: Tsion Firew, MD Brian Gilberti, MD https://media.blubrry.com/coreem/content.blubrry.com/coreem/Marburg_Virus.mp3 Download Leave a Comment Tags: Global Health, Infectious Diseases Show Notes Context and the Rwanda Marburg Experience The Threat: Marburg Virus Disease is from the same family as Ebola and has historically had a reported fatality rate as high as 90%. The Outbreak (Sept. 2024): Rwanda declared an MVD outbreak. The initial cases involved a miner, his pregnant wife (who fell ill and died after having a baby), and the baby (who also died). Healthcare Worker Impact: The wife was treated at an epicenter hospital. Eight HCWs were exposed to a nurse who was coding in the ICU; all eight developed symptoms, tested positive within a week, and four of them died. The Turning Point: The outbreak happened in city referral hospitals where advanced medical interventions (dialysis, mechanical ventilation) were available. Rapid Therapeutics Access: Within 10 days of identifying Marburg, novel therapies (experimental drugs and monoclonal antibodies) and an experimental vaccine were made available through diplomacy with the US government/CDC and agencies like WHO, Africa CDC, CEPI and more. The Outcome: This coordinated effort—combini...

October 31 is Halloween and Dr. Jim Wellehan is embracing spooky season for Animal…

October 31 is Halloween and Dr. Jim Wellehan is embracing spooky season for Animal Airwaves Live. An expert on the evolution and ecology of nondomestic animal pathogens, with an emphasis...

For decades, peanut allergies were on the rise in the US. But a study released on October 20 found that peanut allergies in babies and young children are now decreasing. This drop correlates with a change in guidance from the National Institute of Allergy and Infectious Diseases. In 2017, the agency started recommending exposing children to peanuts “early and often.” Since that recommendation, the prevalence of peanut allergies has dropped significantly.Sharon Chinthrajah, a physician specializing in allergies and immunology, churns through the findings with Host Flora Lichtman.  Guest: Dr. Sharon Chinthrajah is a physician specializing in allergy and immunology at the Sean N. Parker Center at Stanford University.Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Plus, to stay updated on all things science, sign up for Science Friday's newsletters.

On episode #92 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 10/9/25 – 10/22/25. Host: Daniel Griffin and Sara Dong Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral Long-term clinical, immunologic, and viral reservoir outcomes in children treated with VRC01LS and 10-1074 monoclonal antibodies in the Tatelo Study (CID) Resistance Analyses of Lenacapavir, Emtricitabine/Tenofovir Alafenamide and Emtricitabine/Tenofovir Disoproxil Fumarate in the PURPOSE 1 and 2 Studies (JID) Susceptibility of measles virus to WHO hand rubs, oral and surface disinfectants (OFID) Measles without rash during acute febrile illness surveillance in Tanzania, 2023-2024 (CID) The 2025 Centers for Disease Control and Prevention Non-Occupational HIV Post-Exposure Prophylaxis Guidelines (CID) Bacterial Paratyphoid fever and relapsing fever in 1812 Napoleon's devastated army (Current Biology) Mass Administration of Azithromycin to Infants in Mali to Reduce Mortality (NEJM) Efficacy and safety of tedizolid in the treatment of acute bacterial skin and skin-structure infections (CMI: Clinical Microbiology and Infection) Zoonotic Escherichia coli and urinary tract infections in Southern California (mBio) Cefdinir Versus Cephalexin for the Treatment of Uncomplicated Urinary Tract Infections (OFID) Fungal The Last of US Season 2 (YouTube) Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus (Journal of Antimicrobial Chemotherapy) Parasitic Miscellaneous CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant BacteriaCID) Infection Control in Carceral Facilities (CID) Infection Prevention and Control in Carceral Settings (CID) The Challenge of Malignancies in HIV-1, Beyond Immune Activation and Back to Decreased Immune Surveillance (Journal of AIDS & Clinical Research) SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade (Nature) TWiV 1265: mRNA vaccines make cancer treatment great again (microbeTV) Infected With the Academic Bug (CID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

This member-driven podcast is a benefit of membership of the Arizona Chapter of the American Academy of Pediatrics (AzAAP) and is intended for AzAAP pediatric healthcare members.AzAAP would like to acknowledge the generous support of the podcast by the Arizona Department of Health Services through the Title V Maternal and Child Health Services Block Grant funding. No information or content in this podcast is intended to substitute or replace a consultation with a healthcare provider or specialist. All non-healthcare providers should reach out to their child's pediatrician for guidance. Music: Wallpaper by Kevin MacLeodLink: https://incompetech.filmmusic.io/song/4604-wallpaperLicense: http://creativecommons.org/licenses/by/4.0/ 

Just back from IDWeek 2025 in Atlanta, Luis shares the sessions and posters that defined this year's meeting — from next-generation sequencing and diagnostic stewardship to AI in the microbiology lab and new antimicrobials on the horizon. Tune in for insights on: NGS test utilization and stewardship New β-lactamase inhibitors like nacubactam  AI's growing role in clinical microbiology Tedizolid and the importance of optimizing existing agents

Dr. Kami Kim, Chief of Infectious Diseases at the Division of Infectious Diseases, USF Morsani College of Medicine, reviews one of the few truly emergent infectious diseases, Malaria. Dr. Kim begins by discussing the differential of fever in the returning traveller. Next focusing on Plasmodium, she discusses diagnostic techniques, including thick and thin smears and Malaria rapid diagnostic tests. Similarities and differences of the individual species of Plasmodium are next discussed, including Falciparum, Vivax, Ovale, and Malariae. Lastly, the complications of Malaria infection are covered, followed by a brief discussion regarding Dengue virus disease.

This episode tracks a fast-moving week from a U.S. radar request in Grenada and CARICOM's firm stance on sovereignty to Haiti's coordinated security push and BVI customs crackdowns. Here are some of the stories making Caribbean headlines.OECS supports Grenada amid U.S. radar requestCARICOM commitment to a zone of peace and sovereigntyJoint security operations in Haiti to reopen routes and protect infrastructureBVI customs intercepts gun parts and cash; scanners deployedDominican Republic Society of Infectious Diseases urges cross-border health surveillance with resurgence of cholera in HaitiP&O Cruises now offers Barbados beach wedding packagesGrenada's tourism profile rises with top awardsListen and subscribe to the  Pulse of the Caribbean Caribbean News Round Up for news you need to know.Send news releases to news@pulseofthecaribbean.com. For Pulse of the Caribbean marketplace feature opportunities email biz@pulseofthecaribbean.com. Like and follow us on Facebook.

The childhood immunization schedule is one of the defining pillars of pediatric practice and remains among the most successful public health achievements of the modern era. Yet, in recent months, the schedule and the systems that support it have faced new challenges, raising serious concerns for pediatricians across the country. This episode was recorded live at the 2025 American Academy of Pediatrics National Conference in Denver, Colorado. In this episode, we discuss the latest AAP vaccine updates and the evolving landscape of childhood immunizations. Sue Kressly, MD, is a general pediatrician as well as the President of the AAP. Sean O'Leary, MD, is a pediatric infectious disease specialist at Children's Colorado and a professor at the University of Colorado School of Medicine. He is also chair of the AAP Committee on Infectious Diseases, otherwise known as the Red Book Committee. Some highlights from this episode include:  The latest AAP immunization guidance and policy updates  Changes currently impacting pediatricians  Insight into the near future of vaccine distributions  Strategies for combatting confusion and shifting vaccine confidence  For more information on Children's Colorado, visit: childrenscolorado.org. 

In episode 94 of Venture Everywhere the host is Cristian Ponce the CEO of Tetsuwan Scientific, an early-stage company developing software to help scientists operate laboratory automation systems. He talks with Dr. Niamh O'Hara, co-founder and CEO of Biotia, a healthtech company using genomics and AI to fight infectious diseases. She shares how a vision to modernize diagnostics and close the gap in infectious disease detection inspired her to spin Biotia out of Cornell Tech and bring precision metagenomics to market. She opens up about how Biotia bridges the worlds of science and entrepreneurship to accelerate the future of infectious disease diagnostics.In this episode, you will hear:Advancing infectious disease testing with genomics and AITurning academic research into scalable healthtech innovationBuilding faster, more precise pathogen detection toolsCombating antimicrobial resistance through smarter diagnosticsExpanding into women's health and clinical partnershipsLearn more about Niamh O'Hara | BiotiaLinkedIn: https://www.linkedin.com/in/niamh-b-o-hara Website: https://www.biotia.io Learn more about Cristian Ponce | Tetsuwan ScientificLinkedin: https://www.linkedin.com/in/cristian-ponce5 Website: https://tetsuwan.com

En este episodio en español de Let 's Talk Micro, el Dr. Germán Esparza Sánchez , microbiólogo clínico, miembro del CLSI y consultor de la OPS/OMS, comparte las actualizaciones más recientes del documento M100 y cómo impactan la práctica microbiológica. Desde la eliminación de puntos de corte para Burkholderia cepacia hasta los nuevos antibióticos como aztreonam-avibactam, durlobactam-sulbactam y cefiderocol, analizamos los retos de aplicar las guías del CLSI en los laboratorios latinoamericanos, las diferencias epidemiológicas regionales y la importancia de la educación continua para combatir la resistencia antimicrobiana (RAM). Además, el Dr. Esparza comenta sobre el trabajo regional que realizan organizaciones como la Asociación Panamericana de Infectología (API) y COLABIOCLI, que promueven la colaboración científica y la mejora de los laboratorios en América Latina.  Enlaces mencionados Asociación Panamericana de Infectología (API) COLABIOCLI Organización Panamericana de la Salud (OPS) Organización Mundial de la Salud (OMS)   Conéctate con Let's Talk Micro: Página web: letstalkmicro.com ¿Preguntas o comentarios?

Professor Matteo Iannacone is Director of the Division of Immunology, Transplantation and Infectious Diseases, Professor of Pathology, and Head of the Dynamics of Immune Responses laboratory at Vita-Salute San Raffaele University. His work centers on understanding the generation of dysfunctional adaptive immune cells in chronic hepatitis B virus infection and developing new strategies to reprogram them into functional cells endowed with potent antiviral activity.

AP correspondent Ed Donahue reports the U.S. is a no-show at a medical conference.

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Chagas Disease from the Infectious Disease section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Dr. Na-Ri Oh is a physician, biopharmaceutical executive with 15+ years of experience, biotech investor, and healthcare podcast host.As Managing Director and Co-Founder of Black Canyon Ventures, Na-Ri invests in early-stage biotech companies, especially those focusing on rare diseases. Prior, she held roles in global marketing and strategy at Top 20 biopharmaceutical companies, bringing life-saving medicines to patients across six continents. Before her time in biopharma, Na-Ri worked as an Infectious Disease physician, primarily in HIV medicine.In her free time, Na-Ri co-hosts The Real Pharma podcast, where she explores healthcare topics with industry pathfinders.Chapters:00:00 Introduction to Iconic Conversations01:54 Dr. Na-Ri Oh: A Journey in Healthcare and Investment03:45 The Shift Towards Health and Wellness08:26 AI's Role in the Future of Healthcare11:49 Cultural Identity and Growing Up Between Worlds16:43 The American Dream: Opportunities and Challenges20:15 Choosing Positivity in a Complex World21:38 The Ripple Effect of Kindness25:51 Finding Happiness and Contentment29:19 Embracing Change and New Challenges30:15 Innovating Drug Development for Rare Diseases36:22 Philosophical Insights on Life and MaturityLinks: GUEST: Dr. Na-Ri Oh

In this episode of Communicable, Erin McCreary and Angela Huttner are joined by Barbara Trautner (St. Louis, USA) and Valéry Lavergne (Vancouver, Canada), the co-chairs and leading authors of the first IDSA guideline on complicated urinary tract infection (cUTI), which was published a few months ago [1]. Together, they discuss the process of developing the guideline from its conception in 2018, the new definition of cUTI, their stepwise approach to clinical decision-making, and some case-by-case scenarios for common antibiotics. They also elaborate on how this guideline compares (and contrasts) to other existing UTI guidelines—including the previous IDSA guideline for UTI [2] —and the clinical need to supply frontline clinicians to identify and distinguish complicated cases from the uncomplicated ones. The episode closes with what essential clinical questions the guests hope to tackle next.  This episode was edited by Kathryn Hostettler and peer reviewed by Maria Ana Flores of Santa Maria Local Health Unit, Lisbon, Portugal.Other resources:European Urologic Association guidelinesUpToDateFDA guidance on complicated UTI ReferencesTrautner BW, et al. Clinical Practice Guideline by Infectious Diseases Society of America (IDSA): 2025 Guideline on Management and Treatment of Complicated Urinary Tract Infections Gupta, K, et al. Clinical Practice Guidelines for the Treatment of Acute Uncomplicated Cystitis and Pyelonephritis in Women: 2010 Update by IDSA

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Aspergillosis⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ from the Infectious Disease section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

In this episode, we review the high-yield topic ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Human Papilloma Virus⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ from the Infectious Disease section at ⁠⁠⁠⁠Medbullets.com⁠⁠⁠⁠⁠⁠Follow⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media:Facebook: www.facebook.com/medbulletsInstagram: www.instagram.com/medbulletsofficialTwitter: www.twitter.com/medbulletsLinkedin: https://www.linkedin.com/company/medbullets

Fear is one of the earliest emotions to have evolved. Most vertebrates – and possibly some invertebrates – show fear when they are threatened. At its most core, fear keeps us alive, helping us flee from predators or avoid dangerous environments. But why does this process sometimes backfire, leaving us paralysed by otherwise harmless phobias? And why do so many people deliberately seek out fearful situations, from horror movies to parachute jumps, when instinct tells us to do the opposite? Can understanding the biology of fear help us conquer it, or simply make us more vulnerable to its impact?This lecture was recorded by Robin May on the 1st of October 2025 at Bernards Inn Hall, LondonProfessor of Infectious Disease at the University of Birmingham, and (interim) Chief Scientist at the UK Health Security Agency, Robin May was appointed Gresham Professor of Physic in May 2022. Between July 2020 and September 2025 he served as Chief Scientific Adviser at the Food Standards Agency (FSA). Professor May's early training was in Plant Sciences at the University of Oxford, followed by a PhD on mammalian cell biology at University College London and the University of Birmingham. After postdoctoral research on gene silencing at the Hubrecht Laboratory, The Netherlands, he returned to the UK in 2005 to establish a research program on human infectious diseases. He was Director of the Institute of Microbiology and Infection at the University of Birmingham from 2017-2020. Professor May continues his work on Infectious Disease at the University of Birmingham. A Fellow of the Academy of Medical Sciences, Wolfson Royal Society Research Merit Fellow and Fellow of the American Academy of Microbiology, Professor May specialises in research into human infectious diseases, with a particular focus on how pathogens survive and replicate within host organisms.As the FSA's Chief Scientific Adviser, Professor May provides expert scientific advice to the UK government and plays a critical role in helping to understand how scientific developments will shape the work of the FSA, as well as the strategic implications of any possible changes.The transcript of the lecture is available from the Gresham College website: https://www.gresham.ac.uk/watch-now/why-fearGresham College has offered free public lectures for over 400 years, thanks to the generosity of our supporters. There are currently over 2,500 lectures free to access. We believe that everyone should have the opportunity to learn from some of the greatest minds. To support Gresham College's mission, please consider making a donation: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-today Website:  https://gresham.ac.ukX: https://x.com/GreshamCollegeFacebook: https://facebook.com/greshamcollegeInstagram: https://instagram.com/greshamcollegeBluesky: https://bsky.app/profile/greshamcollege.bsky.social TikTok: https://www.tiktok.com/@greshamcollegeSupport Us: https://www.gresham.ac.uk/get-involved/support-us/make-donation/donate-todaySupport the show

Puerto Rico is entering a new era in microbiome research. In this episode,  Luis speaks with Dr. Filipa Godoy-Vitorino about the newly established Microbiome Center of Puerto Rico — a hub designed to strengthen research, collaboration, and training across the Caribbean. Dr. Godoy-Vitorino shares how the center is helping scientists access expertise in bioinformatics and data analysis, offering bilingual workshops, and expanding representation of Caribbean populations in global microbiome studies. She also discusses the center's vision to connect with international partners, support local innovation, and create opportunities for the next generation of researchers.

Don't settle! Listen in to learn how a proactive approach to ART switch can improve treatment satisfaction and quality of life for people living with virologically suppressed HIV. Topics covered include:International AIDS Society (IAS) USA and European AIDS Clinical Society (EACS) Guidance on Switching ART With Viral SuppressionConsiderations for switching to a 2-drug regimen or long-acting ARTMethods for assessing patient satisfaction with their current ART regimenPresenters:Monica Gandhi, MD, MPHDirector, UCSF-Bay Area Center for AIDS Research (CFAR)Professor of Medicine and Associate Chief, Division of HIV, Infectious Diseases, and Global MedicineMedical Director, “Ward 86” HIV Clinic, San Francisco General HospitalUniversity of California, San Francisco (UCSF)San Francisco, CaliforniaLuis Buzon Martin, MDDivision of Infectious DiseasesHospital Universitario de BurgosBurgos, EspanaLink to full program and accompanying slides: https://bit.ly/3KPN0xbGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this powerful episode of The Birth Lounge Podcast, HeHe sits down with infectious disease scientist, Ellie to pull back the curtain on what's really behind vaccines, immunity, and medical ethics. After years working in big pharma, Ellie began questioning what she saw from the inside, and now she's here to help parents unpack the complex, often confusing world of vaccine science through an evidence-based, transparent lens. Together, HeHe and Ellie dive into everything from the ingredients found in common vaccines (and why they're there!) to the differences between live and attenuated viruses. They also explore the ethics of vaccine research, including the use of fetal cell lines, vaccinated vs. unvaccinated clinical trials, and how informed consent fits into modern medicine. This conversation isn't about fear, it's about facts. It's about asking better questions, understanding your options, and feeling confident in the choices you make for your family's health. Ellie brings scientific clarity, a refreshing dose of honesty, and a deep respect for parental autonomy to this nuanced conversation. If you've ever wanted a clearer understanding of vaccines and the ethics behind them, this episode is a must-listen. 03:27 Announcing the New Course: Pushing Out Your Big Ass Baby 05:34 Vaccine Exploration Series Finale 06:19 Ingredients in Vaccines: What You Need to Know 07:35 Interview with Infectious Disease Scientist Ellie 12:11 Ellie's Journey from Big Pharma to Vaccine Skepticism 40:44 Ethical and Scientific Concerns in Vaccine Development 01:02:33 Pharmaceutical Interactions and Clinical Trials 01:04:28 Autonomy and Vaccine Mandates 01:05:17 Herd Immunity and Vaccine Efficacy 01:06:38 Transparency and Trust in Healthcare 01:15:49 Ethics of Vaccine Studies 01:19:12 Challenges in Scientific Research 01:23:55 Vaccine Ingredients and Allergies 01:26:42 Live vs. Attenuated Vaccines 01:29:49 Shingles and Vaccine History 01:33:43 Scientific Communication and Public Trust 01:43:08 Final Thoughts and Resources   Guest Bio: Ellie is an infectious disease scientist with a powerful personal story and a passion for making science accessible. With a B.S. in Cellular and Molecular Biology and an M.S. in Infectious Diseases and Microbiology, Ellie has spent years on the front lines of science—from developing vaccines for potential bioweapons during her graduate research to working in assay development and infectious disease research within the pharmaceutical industry. Four years ago, she made the bold decision to step away from pharma and pursue a path that blends science, personal experience, and public education. Ellie was born with a left radial clubbed hand, congenital heart issues, and other challenges caused by a pharmaceutical product—an experience that has shaped her unique perspective on medicine. After undergoing countless surgeries, she deeply understands the life-saving value of western medicine, while also recognizing that alternatives can have a place in care. Ellie now dedicates herself to helping people understand complex scientific topics so they can make empowered, informed health decisions. She believes that her journey—both scientific and deeply personal—is no accident. Through all the challenges she has faced, she's seen the hand of Jesus guiding her path and believes God has kept her alive for a greater purpose.  INSTAGRAM: Connect with HeHe on IG  Connect with Ellie on IG    BIRTH EDUCATION: Join The Birth Lounge here for judgment-free childbirth education that prepares you for an informed birth and how to confidently navigate hospital policy to have a trauma-free labor experience!   Download The Birth Lounge App for birth & postpartum prep delivered straight to your phone!   RESOURCES MENTIONED: https://cogforlife.org/  https://www.cellosaurus.org/  You can search a variety of ways in the site, but one is 'browse by group' and click 'Vaccine production cell lines' 

On episode #91 of the Infectious Disease Puscast, Daniel reviews the infectious disease literature for the weeks of 9/25/25 – 10/8/25. Host: Daniel Griffin Subscribe (free): Apple Podcasts, RSS, email Become a patron of Puscast! Links for this episode Viral American Academy of Pediatrics Comparison of 2 Doses vs 1 Dose in the First Season Children Are Vaccinated Against Influenza(JAMA: Open Network) Flu and Children (CDC: Influenza (flu)) Bacterial Performance of Different Versions of Duke Criteria in Diagnosing Infective Endocarditis in Patients With Intracardiac Prosthetic (OFID) 2023 Duke criteria on Infectious Disease (Puscast 28) Infective Endocarditis and Antimicrobial Timing: A Case for Delay? (OFID) Tularemia: A Storied History, An Ongoing Threat (CID) Tularemia Antimicrobial Treatment and Prophylaxis: CDC Recommendations for Naturally Acquired Infections and Bioterrorism Response — United States, 2025 (CDC: MMWR) Fungal The Last of US Season 2 (YouTube) Risk factors associated with progression to clinical Candida auris infection among adults with previous colonization—Florida, 2019–2023 (CID) Parasitic Public Health Response to the First Locally Acquired Malaria Outbreaks in the US in 20 Years (JAMA: Open Network) Miscellaneous Fever in sepsis revisited: Is a little heat what we need? (OFID) Music is by Ronald Jenkees Information on this podcast should not be considered as medical advice.

Before a body is ever opened, a medical examiner must consider what dangers might be waiting inside: fentanyl, tuberculosis or even a hidden needle. This week on Pathology with Dr. Priya, a Zone 7 series, Sheryl McCollum and Dr. Priya Banerjee share stories from their recent visit to Lake Tobias Wildlife Park. There, they took part in Wildlife CSI training, a hands-on blend of forensic education and animal encounters, including time with Chester, a baby kangaroo who quickly won everyone over. From there, the conversation shifts to the serious risks medical examiners face every day. From bloodborne pathogens and drug exposure to unstable death scenes and unpredictable infections, Dr. Priya offers a closer look at the hidden hazards behind every autopsy. Highlights (0:00) Welcome to Pathology with Dr. Priya: A Zone 7 series—Sheryl and Dr. Priya open the episode with highlights from the Wildlife CSI training at Lake Tobias Wildlife Park (3:15) Embracing lifelong learning, from seasoned investigators to students in the field (4:45 Honoring Dr. Jane Goodall and recognizing how wildlife crime intersects with forensic science (6:30) The hidden dangers of autopsy work: COVID, drug exposure, and unknown infections (8:30) Safety in the morgue: scalpel slips, needle sticks, and the rise of pandemic-era protocols (12:30) Fentanyl, MRSA, TB, and the health risks involved in cases with limited medical histories or unidentified individuals (17:00) Environmental hazards at the death scene, from fire damage and rough terrain to unpredictable animals (22:15) Morgue myths, pet protection, and why even the smallest details can carry big dangers About the Hosts Dr. Priya Banerjee is a board-certified forensic pathologist with extensive experience in death investigation, clinical forensics, and courtroom testimony. A graduate of Johns Hopkins, she served for over a decade as Rhode Island’s state medical examiner and now runs a private forensic pathology practice. Her work includes military deaths, NSA cases, and high-profile investigations. Dr. Priya has also been featured as a forensic expert on platforms such as CrimeOnline and Crime Stories with Nancy Grace. She is a dedicated educator, animal lover, and proud mom. Website: anchorforensicpathology.comTwitter/X: @Autopsy_MD Sheryl McCollum is an Emmy Award–winning CSI, a writer for CrimeOnline, and the Forensic and Crime Scene Expert for Crime Stories with Nancy Grace. She works as a CSI for a metro Atlanta Police Department and is the co-author of the textbook Cold Case: Pathways to Justice. Sheryl is also the founder and director of the Cold Case Investigative Research Institute (CCIRI), a nationally recognized nonprofit that brings together universities, law enforcement, and experts to help solve unsolved homicides, missing persons cases, and kidnappings. Email: coldcase2004@gmail.comTwitter/X: @ColdCaseTipsFacebook: @sheryl.mccollumInstagram: @officialzone7podcast

In this second half of our discussion with Dr. Erin McCreary and Dr. Hannah Creager, we dive deeper into how microbiology and antimicrobial stewardship teams collaborate to improve patient outcomes. They unpack how to prioritize breakpoint updates, the pros and cons of cascade reporting, and what nudges can do to guide better prescribing. Then we explore a powerful example of collaboration—the transition from MRSA agar to PCR across hospitals—and what it taught both teams about communication, resource sharing, and patient safety. Finally, Erin and Hannah reflect on lessons learned, first steps for building collaboration, and even share their favorite microbes (spoiler: both picked viruses!).

The Nobel Prize in physiology or medicine was awarded to three scientists for their work in immunology.  Daniel Griffin, MD, PhD, Chief of Infectious Disease for Island Infectious Diseases, the largest physician-owned Infectious Disease Specialist Group on Long Island, an infectious disease specialist and clinical instructor of medicine at Columbia University and president of Parasites Without Borders and co-host of the podcast "This Week in Virology", explains their breakthrough and what it means for future treatments for autoimmune diseases, cancer, and more. 

About this episode: For centuries, public health has seen invisible killers, believed in the power of community interventions, and created better health outcomes across the globe. In this episode: Former CDC director Tom Frieden explains how to tackle today's biggest health challenges and previews his new book, “The Formula for Better Health: How to Save Millions of Lives—Including Your Own”. Guest: Dr. Tom Frieden, MPH, is the president and CEO of Resolve to Save Lives. He previously served as the director of the CDC and is the author of “The Formula for Better Health: How to Save Millions of Lives—Including Your Own”. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: The Formula for Better Health: How to Save Millions of Lives—Including Your Own—Penguin Random House A former CDC director's guide to seeing and stopping threats to America's health—STAT Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

These diseases - West Nile Virus, Lyme disease, and Rocky Mountain Spotted Fever - are named for the places where outbreaks happened. But they're also all things you get from being bitten by mosquitoes or ticks. Research: Balasubramanian, Chandana. “Rocky Mountain Spotted Fever (RMSF): The Deadly Tick-borne Disease That Inspired a Hit Movie.” Gideon. 9/1/2022. https://www.gideononline.com/blogs/rocky-mountain-spotted-fever/ Barbour AG, Benach JL2019.Discovery of the Lyme Disease Agent. mBio10:10.1128/mbio.02166-19.https://doi.org/10.1128/mbio.02166-19 Bay Area Lyme Foundation. “History of Lyme Disease.” https://www.bayarealyme.org/about-lyme/history-lyme-disease/ Caccone, Adalgisa. “Ancient History of Lyme Disease in North America Revealed with Bacterial Genomes.” Yale School of Medicine. 8/28/2017. https://medicine.yale.edu/news-article/ancient-history-of-lyme-disease-in-north-america-revealed-with-bacterial-genomes/ Chowning, William M. “Studies in Pyroplasmosis Hominis.("Spotted Fever" or "Tick Fever" of the Rocky Mountains.).” The Journal of Infectious Diseases. 1/2/1904. https://archive.org/details/jstor-30071629/page/n29/mode/1up Elbaum-Garfinkle, Shana. “Close to home: a history of Yale and Lyme disease.” The Yale journal of biology and medicine vol. 84,2 (2011): 103-8. Farris, Debbie. “Lyme disease older than human race.” Oregon State University. 5/29/2014. https://science.oregonstate.edu/IMPACT/2014/05/lyme-disease-older-than-human-race Galef, Julia. “Iceman Was a Medical Mess.” Science. 2/29/2012. https://www.science.org/content/article/iceman-was-medical-mess Gould, Carolyn V. “Combating West Nile Virus Disease — Time to Revisit Vaccination.” New England Journal of Medicine. Vol. 388, No. 18. 4/29/2023. https://www.nejm.org/doi/full/10.1056/NEJMp2301816 Harmon, Jim. “Harmon’s Histories: Montana’s Early Tick Fever Research Drew Protests, Violence.” Missoula Current. 7/20/2020. https://missoulacurrent.com/ticks/ Hayes, Curtis G. “West Nile Virus: Uganda, 1937, to New York City, 1999.” From West Nile Virus: Detection, Surveillance, and Control. New York : New York Academy of Sciences. 2001. https://archive.org/details/westnilevirusdet0951unse/ Jannotta, Sepp. “Robert Cooley.” Montana State University. 10/12/2012. https://www.montana.edu/news/mountainsandminds/article.html?id=11471 Johnston, B L, and J M Conly. “West Nile virus - where did it come from and where might it go?.” The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses vol. 11,4 (2000): 175-8. doi:10.1155/2000/856598 Lloyd, Douglas S. “Circular Letter #12 -32.” 8/3/1976. https://portal.ct.gov/-/media/departments-and-agencies/dph/dph/infectious_diseases/lyme/1976circularletterpdf.pdf Mahajan, Vikram K. “Lyme Disease: An Overview.” Indian dermatology online journal vol. 14,5 594-604. 23 Feb. 2023, doi:10.4103/idoj.idoj_418_22 MedLine Plus. “West Nile virus infection.” https://medlineplus.gov/ency/article/007186.htm National Institute of Allergy and Infectious Disease. “History of Rocky Mountain Labs (RML).” 8/16/2023. https://www.niaid.nih.gov/about/rocky-mountain-history National Institute of Allergy and Infectious Disease. “Rocky Mountain Spotted Fever.” https://www.niaid.nih.gov/diseases-conditions/rocky-mountain-spotted-fever Rensberger, Boyce. “A New Type of Arthritis Found in Lyme.” New York Times. 7/18/1976. https://www.nytimes.com/1976/07/18/archives/a-new-type-of-arthritis-found-in-lyme-new-form-of-arthritis-is.html?login=smartlock&auth=login-smartlock Rucker, William Colby. “Rocky Mountain Spotted Fever.” Washington: Government Printing Office. 1912. https://archive.org/details/101688739.nlm.nih.gov/page/ Sejvar, James J. “West Nile virus: an historical overview.” Ochsner journal vol. 5,3 (2003): 6-10. https://pmc.ncbi.nlm.nih.gov/articles/PMC3111838/ Smithburn, K.C. et al. “A Neurotropic Virus Isolated from the Blood of a Native of Uganda.” The American Journal of Tropical Medicine and Hygiene. Volume s1-20: Issue 4. 1940. Steere, Allen C et al. “The emergence of Lyme disease.” The Journal of clinical investigation vol. 113,8 (2004): 1093-101. doi:10.1172/JCI21681 Steere, Allen C. et al. “Historical Perspectives.” Zbl. Bakt. Hyg. A 263, 3-6 (1986 ). https://pdf.sciencedirectassets.com/281837/1-s2.0-S0176672486X80912/1-s2.0-S0176672486800931/main.pdf World Health Organization. “West Nile Virus.” 10/3/2017. https://www.who.int/news-room/fact-sheets/detail/west-nile-virus Xiao, Y., Beare, P.A., Best, S.M. et al. Genetic sequencing of a 1944 Rocky Mountain spotted fever vaccine. Sci Rep 13, 4687 (2023). https://doi.org/10.1038/s41598-023-31894-0 See omnystudio.com/listener for privacy information.

About this episode: Last week, Dr. Debra Houry was testifying before Congress. Today, she's talking with Dr. Josh Sharfstein on Public Health On Call. In this episode: Dr. Houry reflects on her time at the CDC, the drastic changes at the agency under Health and Human Services Secretary Robert F. Kennedy Jr., and what she hopes her testimony can do to uphold quality public health. Guest: Dr. Debra Houry, MPH, most recently served as the Chief Medical Officer and Deputy Director for Program and Science at the CDC. She has also worked as a professor at both the Emory University School of Medicine and the Rollins School of Public Health, and as an emergency department physician. Host: Dr. Josh Sharfstein is distinguished professor of the practice in Health Policy and Management, a pediatrician, and former secretary of Maryland's Health Department. Show links and related content: Testimony from Debra Houry, M.D., M.P.H.—Senate Committee on Health, Education, Labor, and Pensions Senior CDC officials resign after Monarez ouster, cite concerns over scientific independence—CBS News A Brief Update: CDC in Crisis—Public Health On Call (September 2025) Transcript information: Looking for episode transcripts? Open our podcast on the Apple Podcasts app (desktop or mobile) or the Spotify mobile app to access an auto-generated transcript of any episode. Closed captioning is also available for every episode on our YouTube channel. Contact us: Have a question about something you heard? Looking for a transcript? Want to suggest a topic or guest? Contact us via email or visit our website. Follow us: @‌PublicHealthPod on Bluesky @‌JohnsHopkinsSPH on Instagram @‌JohnsHopkinsSPH on Facebook @‌PublicHealthOnCall on YouTube Here's our RSS feed Note: These podcasts are a conversation between the participants, and do not represent the position of Johns Hopkins University.

Brooke Gladstone speaks with Paul Offit, the director of the Vaccine Education Center and a physician in the Division of Infectious Diseases at Children's Hospital of Philadelphia, about how the Secretary of Health and Human Services, Robert F. Kennedy Jr., purged the CDC's vaccine advisory committee members, the controversial figures Kennedy replaced them with, and what impact this will have on the future of vaccines and immunology in the US.  On the Media is supported by listeners like you. Support OTM by donating today (https://pledge.wnyc.org/support/otm). Follow our show on Instagram, Twitter and Facebook @onthemedia, and share your thoughts with us by emailing onthemedia@wnyc.org.